DK1594970T3 - Fremgangsmåde til generering af rekombinant MVA - Google Patents

Fremgangsmåde til generering af rekombinant MVA

Info

Publication number
DK1594970T3
DK1594970T3 DK04712013T DK04712013T DK1594970T3 DK 1594970 T3 DK1594970 T3 DK 1594970T3 DK 04712013 T DK04712013 T DK 04712013T DK 04712013 T DK04712013 T DK 04712013T DK 1594970 T3 DK1594970 T3 DK 1594970T3
Authority
DK
Denmark
Prior art keywords
recombinant mva
mva
generating recombinant
dna
generation
Prior art date
Application number
DK04712013T
Other languages
English (en)
Inventor
Caroline Staib
Marianne Loewel
Volker Erfle
Gerd Sutter
Original Assignee
Helmholtz Zentrum Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum Muenchen filed Critical Helmholtz Zentrum Muenchen
Application granted granted Critical
Publication of DK1594970T3 publication Critical patent/DK1594970T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK04712013T 2003-02-18 2004-02-18 Fremgangsmåde til generering af rekombinant MVA DK1594970T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44823103P 2003-02-18 2003-02-18
PCT/EP2004/001554 WO2004074493A1 (en) 2003-02-18 2004-02-18 Recombinant mva and method for generation thereof

Publications (1)

Publication Number Publication Date
DK1594970T3 true DK1594970T3 (da) 2008-11-17

Family

ID=32908561

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04712013T DK1594970T3 (da) 2003-02-18 2004-02-18 Fremgangsmåde til generering af rekombinant MVA

Country Status (8)

Country Link
US (1) US20060002896A1 (da)
EP (1) EP1594970B1 (da)
JP (2) JP4686443B2 (da)
CN (1) CN1723285B (da)
AT (1) ATE403005T1 (da)
DE (1) DE602004015418D1 (da)
DK (1) DK1594970T3 (da)
WO (1) WO2004074493A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
WO2004058801A2 (en) 2002-12-23 2004-07-15 City Of Hope Modified vaccinia ankara expressing p53 in cancer immunotherapy
EP2199400A1 (en) * 2008-12-22 2010-06-23 Emergent Product Development Germany GmbH Single recombination system and methods of use
CN102559611B (zh) * 2011-06-23 2015-04-22 江苏省农业科学院 一种无筛选标记的双表达重组mva病毒及其构建方法
MX2018010231A (es) * 2016-02-25 2019-06-06 Memorial Sloan Kettering Cancer Center Mva recombinante o mvadele3l que expresa el flt3l humano y uso de los mismos como agentes inmunoterapéuticos contra tumores sólidos.
MX2019001919A (es) * 2016-08-19 2019-09-04 Sementis Ltd Vacunas virales.
EP3928789A1 (en) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP4358999A1 (en) 2021-06-23 2024-05-01 Consejo Superior De Investigaciones Científicas Mva-based vaccine expressing a prefusion-stabilized sars-cov-2 s protein
EP4108257A1 (en) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
EP4316514A1 (en) 2022-08-03 2024-02-07 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vectors and their use as vaccine against sars-cov-2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015672A1 (en) * 1991-03-07 1992-09-17 Virogenetics Corporation Genetically engineered vaccine strain
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
CA2282300C (en) * 1997-02-24 2011-08-02 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
EP1283718A2 (en) * 2000-05-24 2003-02-19 Merial Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
GB0111442D0 (en) * 2001-05-10 2001-07-04 Isis Innovation Method for preparing recombinant virus

Also Published As

Publication number Publication date
CN1723285A (zh) 2006-01-18
JP5166505B2 (ja) 2013-03-21
ATE403005T1 (de) 2008-08-15
DE602004015418D1 (de) 2008-09-11
JP2011055840A (ja) 2011-03-24
US20060002896A1 (en) 2006-01-05
EP1594970A1 (en) 2005-11-16
JP4686443B2 (ja) 2011-05-25
WO2004074493A1 (en) 2004-09-02
CN1723285B (zh) 2013-01-02
EP1594970B1 (en) 2008-07-30
JP2006517795A (ja) 2006-08-03

Similar Documents

Publication Publication Date Title
MX2019012940A (es) Metodos para producir edulcorantes de alta intensidad.
EA201001491A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
DE602004028468D1 (de) Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke
NO20073065L (no) Injiserbare nanopartikulaere olanzapinformuleringer
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
NO20056074L (no) Hoy titer rekombinante influensavira til vaksiner og genterapi
DK1594970T3 (da) Fremgangsmåde til generering af rekombinant MVA
BRPI0817299A8 (pt) vacinas e componentes de vacina para inibição de células microbianas
AU2016204319A1 (en) Methods and compositions for producing squalene using yeast
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
DK1644348T3 (da) Epoxy-afsluttede polythioethere, Epoxy-afsluttede polythioethere
HRP20041085B1 (hr) Inhibitori hepatitis c virusa
WO2001064835A8 (en) Novel nucleic acids and polypeptides
TW200632614A (en) Voltage reference generator and method of generating a reference voltage
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
DE60126785D1 (de) Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
DK1877390T3 (da) Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf
NO20063332L (no) Kerosenblanding
EA200701665A1 (ru) Композиция и способ получения проппанта
BRPI0414463A (pt) ácidos heteroarilbenzofuránicos substituìdos
DK2089516T3 (da) Fremgangsmåder til at forbedre indføringen af DNA i bakterielle celler
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
PH12021550997A1 (en) Methods for making high intensity sweeteners
WO2006138441A3 (en) Boost devices and methods of using them